Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $3.68 Million Holdings in Intuitive Surgical, Inc. $ISRG

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 25.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,001 shares of the medical equipment provider’s stock after selling 2,340 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Intuitive Surgical were worth $3,676,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in shares of Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after purchasing an additional 731 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 268 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth $200,000. Finally, Main Street Financial Solutions LLC lifted its position in shares of Intuitive Surgical by 92.4% during the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after purchasing an additional 1,407 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 7.2%

Shares of NASDAQ ISRG opened at $483.62 on Thursday. The company has a market cap of $171.75 billion, a P/E ratio of 58.62, a P/E/G ratio of 3.52 and a beta of 1.68. Intuitive Surgical, Inc. has a 52 week low of $427.84 and a 52 week high of $603.88. The business has a 50-day simple moving average of $477.54 and a two-hundred day simple moving average of $515.41.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.96% and a net margin of 28.15%.The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The company’s revenue was up 23.0% on a year-over-year basis. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.16 EPS for the current year.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q1 results materially beat expectations — revenue $2.77B (+23% y/y) and non?GAAP EPS $2.50 vs. consensus ~$2.08; company raised its full?year procedure growth guidance, which underpins upside to recurring instrument/consumable sales. Why Intuitive Surgical (ISRG) Stock Is Up Today
• Positive Sentiment: Procedure and platform adoption remain the growth engine: da Vinci procedures grew ~16%, Ion procedures ~39%, and management highlighted placements/usage for the new da Vinci 5 — supporting longer?term recurring revenue. Intuitive Announces First Quarter Earnings
• Positive Sentiment: Analysts reacted by raising some forecasts and price targets (Goldman, Baird among those nudging targets higher), and several firms reiterated Buy/Outperform ratings after the beat — providing further near?term support. Intuitive Surgical Analysts Boost Their Forecasts After Upbeat Q1 Earnings
• Positive Sentiment: Management emphasized expansion of digital and AI?enabled surgical capabilities and secured new FDA clearances — strategic catalytic items for long?term TAM expansion and higher?margin software/services revenue. Intuitive Surgical Balances Growth In AI Surgery With Cybersecurity Lessons
• Neutral Sentiment: Earnings call color: management raised its 2026 da Vinci procedure growth guide (roughly 13.5%–15.5%) and described international headwinds as manageable — positive directional detail but partly conservative on full?year trajectory. Intuitive Surgical Earnings Call Signals Robust Growth
• Negative Sentiment: The company disclosed a recent cyber incident described as contained with remediation underway — a reputational and operational risk that investors will watch for any customer or regulatory fallout. Intuitive Surgical Balances Growth In AI Surgery With Cybersecurity Lessons
• Negative Sentiment: Valuation and caution remain: several firms trimmed price targets or tempered estimates (Jefferies, TD Cowen and others adjusted targets), and some commentators warn investors not to overpay despite high?quality growth — keeping volatility likely. TD Cowen Adjusts Price Target on Intuitive Surgical

Analyst Ratings Changes

ISRG has been the topic of a number of research analyst reports. Truist Financial cut their target price on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Barclays set a $651.00 price target on shares of Intuitive Surgical in a research report on Thursday. HSBC lifted their price objective on shares of Intuitive Surgical from $644.00 to $653.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Zacks Research downgraded shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Finally, Wall Street Zen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Eighteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $584.04.

Insider Activity

In other Intuitive Surgical news, EVP Myriam Curet sold 105 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total value of $51,864.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Fredrik Widman sold 133 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total transaction of $65,829.68. Following the completion of the transaction, the vice president directly owned 660 shares in the company, valued at approximately $326,673.60. The trade was a 16.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 32,943 shares of company stock valued at $17,279,568. 0.60% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.